Evaluation of response to different COVID‐19 vaccines in vaccinated healthcare workers in a single center in Iran

Pourakbari, Babak; Mirbeyk, Mona; Mahmoudi, Shima; Sadeghi, Reihaneh Hosseinpour; Rezaei, Nima; Ghasemi, Raheleh; Esfandiari, Fatemeh; Mamishi, Setareh

doi:10.1002/jmv.28029

Cited by 7 publications

(10 citation statements)

References 43 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Pourakbari and colleagues found a pediatric mortality rate of 10%. 24 In the current study, as with others, an underlying medical condition appears to be a key factor in determining COVID-19 disease in children, but there is a lack of evidence to judge the importance and strength of our findings; therefore, it suggests more research. 25 The small sample size of our study is a main limitation, especially the sample size of patients with SARS-CoV-2 viremia, which may affect the statistical results.…”

Section: Discussionmentioning

confidence: 48%

See 1 more Smart Citation

Comparing clinical presentation, viremia, and immunological factors at various severity presentations in hospitalized children affected by COVID‐19: A cross‐sectional study

Jamalidoust,

Hamzavi,

Shorafa

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Although SARS‐CoV‐2 infection usually leads to mild COVID‐19 in children, sometimes it causes serious complications, especially in those with underlying diseases. Several factors have been identified in determining disease severity in adults, and limited studies have been conducted in children. The prognostic implications of SARS‐CoV‐2 RNaemia as an important factor in determining disease severity in children are not well understood. Methods In this study, we aimed to prospectively assess the relationship between disease severity and immunological factors and viremia in 47 COVID‐19 hospitalized children. In this research, 76.5% of children experienced mild and moderate COVID‐19, while 23.5% experienced severe and critical forms of the disease. Results The presence of underlying diseases in different groups of pediatric patients differed significantly from each other. On the other hand, clinical symptoms such as vomiting and chest pain as well as laboratory parameters including erythrocyte sedimentation rate were significantly different in different groups of patients. Viremia was seen in only two children, and this had no significant relationship with the severity of COVID‐19. Conclusion In conclusion, our data confirmed that COVID‐19 severity differed in SARS‐CoV‐2 infected children. Some clinical presentation and lab data parameters were different in various presentation of patients. Viremia was not associated with severity in our study.

show abstract

Section: Discussionmentioning

confidence: 48%

“…However, the current study reports only two deaths (4%) in infants with a complicated underlying medical condition. A study by Pourakbari and colleagues found a pediatric mortality rate of 10% 24 …”

Section: Discussionmentioning

confidence: 99%

Comparing clinical presentation, viremia, and immunological factors at various severity presentations in hospitalized children affected by COVID‐19: A cross‐sectional study

Jamalidoust,

Hamzavi,

Shorafa

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…However, previous studies have applied the ELISA to detect neutralizing antibodies, and the data suggested that using RBD as an immunogen might be a better strategy for creating a robust neutralization Ab response compared with full-length S protein 50 , and the ELISA results were highly responsive to neutralizing antibody levels 51 .…”

Section: The Persistence Of T-cell Immunity Stimulated By Sars-cov-2 ...mentioning

confidence: 99%

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents

Liu

Zhang

Li³

et al. 2023

Preprint

View full text Add to dashboard Cite

For nearly three years, humans have experienced multiple rounds of global transmission of SARS-CoV-2 and its variant strains. In addition, the widely used vaccines against SARS-CoV-2 involve multiple strategies of development and inoculation, globally. Thus, the acquired immunity established among humans is quite complicated, and there is still a lack of understanding within a panoramic vision. Here, we provide the special characteristics of the cellular and humoral immune responses in 2-year convalescents after the inoculation of inactivated vaccine, in parallel to vaccinated COVID-19 naïve persons and unvaccinated controls. The decreasing trends of the IgG, IgA, and neutralizing antibodies (NAb), but not IgM of the convalescents were reversed by the vaccination. Both cellular and humoral immunity to SARS-CoV-2 in convalescents after vaccination were higher than the vaccinated COVID-19 naïve persons. Notably, the inoculation of inactivated vaccine fueled the NAb to Omicron BA.1, BA.2, BA.4, and BA.5 in the 2-year convalescents, much higher than the NAb during 6 months and 1 year after symptoms onset. And no obvious T cell escaping to the S protein was observed after the inoculation in the 2-year convalescents. The study provides insight into the complicated features of acquired immunity of humans to SARS-CoV-2 and variants in the real world, and indicated that promoting vaccine inoculation is an essential way to achieve herd immunity against emerging viral variants for the ongoing COVID-19 pandemic, including the convalescents.

show abstract

“…Although various studies have been carried out to investigate the immunogenicity and reactogenicity of COVID-19 vaccines in various populations, 25 – 27 the efficacy and adverse events of these vaccines in the Iranian population are not well identified so far. Therefore, the aim of this study was to investigate whether the Oxford-AstraZeneca- and Sinopharm vaccines, as the most frequent vaccines used in the national vaccination protocols, had immunogenicity and side effects in healthy individuals and patients with autoimmune disorders in Kashan, Iran.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population

Moradi Hasan-Abad,

Arbabi,

Gilasi

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Introduction: Recent studies have proposed various COVID-19 vaccines to control the disease and protect susceptible individuals. However, immunogenicity and safety of COVID-19 vaccines in various populations are not well identified yet. Therefore, this study aimed to elucidate the efficacy and safety of the BBIBP-CorV (Sinopharm) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in healthy subjects and patients with autoimmune diseases. Methods: Study population included 121 healthy subjects and 100 patients with autoimmune diseases. Immunization was performed based on the national vaccination protocols. Of the 221 volunteers, 201 subjects received Sinopharm and 20 cases were vaccinated with Oxford-AstraZeneca. During a 1-year follow-up, the immunogenicity was measured by ELISA before primary vaccination and 1 to 3 months after secondary immunization. Side effects were studied before entering the study and 1 week after the second dose. Results: Vaccination had a positive impact on the induction of immunogenic response ( p < .0001). The rates of seropositive vaccine responses were 80% and 75% in subjects vaccinated with the Sinopharm and Oxford-AstraZeneca, respectively. The neutralizing antibody values were significantly higher in subjects with autoimmune diseases than those without autoimmunity ( p < .05). The rate of adverse events were 38% and 42% in subjects vaccinated with the Sinopharm and Oxford-AstraZeneca, respectively. The rates of immunogenic responses induced with the Sinopharm and Oxford-AstraZeneca were, respectively, 76% and 81.5% in seropositive subjects, while they were 63.8% and 79.1% in seronegative subjects vaccinated with the Sinopharm and Oxford-AstraZeneca, respectively. Individuals previously infected with SARS-CoV-2 showed a significant reduction in the value of SARS-CoV-2 neutralizing antibodies compared with seronegative subjects ( p < .01–.05). Seropositive individuals vaccinated with the Sinopharm had significantly higher the percentages of vaccine-related adverse events than seronegative persons ( p < .05). There was no significant difference between seronegative and seropositive individuals vaccinated with the Oxford-AstraZeneca. Conclusion: Our findings revealed that the Sinopharm and Oxford-AstraZeneca vaccines are effective in the production of neutralizing antibodies in healthy subjects and patients with autoimmune disorders undergoing immunosuppressive therapies without considerable reactogenicity.

show abstract

Evaluation of response to different COVID‐19 vaccines in vaccinated healthcare workers in a single center in Iran

Cited by 7 publications

References 43 publications

Comparing clinical presentation, viremia, and immunological factors at various severity presentations in hospitalized children affected by COVID‐19: A cross‐sectional study

Comparing clinical presentation, viremia, and immunological factors at various severity presentations in hospitalized children affected by COVID‐19: A cross‐sectional study

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents

Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population

Contact Info

Product

Resources

About